Recombinant Antigen-Based ELISA Evaluated for Syphilis
By LabMedica International staff writers Posted on 28 Aug 2013 |

Image: Photomicrograph of Treponema pallidum (Photo courtesy of Susan Lindsley).
The diagnostic performance of the latest screening enzyme-linked immunosorbent assay (ELISA) for syphilis has been compared with the currently used treponemal tests.
The etiological agent of syphilis, Treponema pallidum, cannot be cultured and there is no single optimal alternative test. Serological testing is the most frequently used approach in laboratory diagnosis of the disease.
Scientists at Sekisui Virotech (Rüsselsheim, Germany) compared their Treponema pallidum Screen ELISA with standard tests. These tests included the fluorescent treponemal antibody absorption (FTA-ABS, Zeus Scientific; Branchburg, NJ, USA) test, which is an indirect fluorescent antibody technique; the T. pallidum particle agglutination (TPPA, Fujirebio; Hoofddorp, the Netherlands) test, which is a qualitative assay for the detection of antibodies to T. pallidum in serum or plasma. The most relevant test used for comparison was the Trep-Sure ELISA (Phoenix Bio-Tech Corporation; Mississauga, ON, Canada).
To establish the sensitivity and specificity of the Virotech Screen, 421 serum samples from different panels of infected and non-infected patients, sera from seronegative pregnant women as well as international syphilis standard sera and panels were tested. In comparison to combined TPPA/FTA-abs tests, Phoenix Trep-Sure and Virotech Screen demonstrated a sensitivity of 100% and a specificity of 93.9% and 98.3%, respectively.
All samples of a well-defined syphilis serum panel were correctly identified by the Virotech test, whereas the Phoenix test identified two Treponema negative samples as equivocal. The Trep Sure test is approved by the US Food and Drug Administration (FDA; Silver Springs, MD, USA). Results of both ELISAs highly correlated with TPPA negative and positive samples. The analytical sensitivity of the Virotech Screen with international standards was determined at 0.02 IU/mL and 0.03 IU/mL, and was slightly superior to the Phoenix Trep-Sure.
The authors concluded that the Virotech Screen ELISA demonstrated good diagnostic sensitivity and specificity when evaluated as a screening test for syphilis among various patient populations, including samples with increased rates of false positive nontreponemal test results. The Virotech ELISA may be used in automatic analyzers as an alternative to the manual TPPA. However, the use of a confirmatory test remains a must in order to avoid false-positive results. The study was published in the May/June, 2013 issue of the journal Clinical Laboratory.
Related Links:
Sekisui Virotech
Zeus Scientific
Fujirebio
The etiological agent of syphilis, Treponema pallidum, cannot be cultured and there is no single optimal alternative test. Serological testing is the most frequently used approach in laboratory diagnosis of the disease.
Scientists at Sekisui Virotech (Rüsselsheim, Germany) compared their Treponema pallidum Screen ELISA with standard tests. These tests included the fluorescent treponemal antibody absorption (FTA-ABS, Zeus Scientific; Branchburg, NJ, USA) test, which is an indirect fluorescent antibody technique; the T. pallidum particle agglutination (TPPA, Fujirebio; Hoofddorp, the Netherlands) test, which is a qualitative assay for the detection of antibodies to T. pallidum in serum or plasma. The most relevant test used for comparison was the Trep-Sure ELISA (Phoenix Bio-Tech Corporation; Mississauga, ON, Canada).
To establish the sensitivity and specificity of the Virotech Screen, 421 serum samples from different panels of infected and non-infected patients, sera from seronegative pregnant women as well as international syphilis standard sera and panels were tested. In comparison to combined TPPA/FTA-abs tests, Phoenix Trep-Sure and Virotech Screen demonstrated a sensitivity of 100% and a specificity of 93.9% and 98.3%, respectively.
All samples of a well-defined syphilis serum panel were correctly identified by the Virotech test, whereas the Phoenix test identified two Treponema negative samples as equivocal. The Trep Sure test is approved by the US Food and Drug Administration (FDA; Silver Springs, MD, USA). Results of both ELISAs highly correlated with TPPA negative and positive samples. The analytical sensitivity of the Virotech Screen with international standards was determined at 0.02 IU/mL and 0.03 IU/mL, and was slightly superior to the Phoenix Trep-Sure.
The authors concluded that the Virotech Screen ELISA demonstrated good diagnostic sensitivity and specificity when evaluated as a screening test for syphilis among various patient populations, including samples with increased rates of false positive nontreponemal test results. The Virotech ELISA may be used in automatic analyzers as an alternative to the manual TPPA. However, the use of a confirmatory test remains a must in order to avoid false-positive results. The study was published in the May/June, 2013 issue of the journal Clinical Laboratory.
Related Links:
Sekisui Virotech
Zeus Scientific
Fujirebio
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more